Loading…
Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka
The clinical application of anthracycline chemotherapy is hindered due to the cumulative dose-dependent cardiotoxicity followed by the oxidative stress initiated during the mechanism of action of anthracyclines. Due to a lack of prevalence data regarding anthracycline-induced cardiotoxicity in Sri L...
Saved in:
| Published in: | BMC cancer 2023-03, Vol.23 (1), p.210-210, Article 210 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c579t-16ad3fad795e9da4450c313b4caf47764379fc99ed3123171ddbce75efc2809b3 |
| container_end_page | 210 |
| container_issue | 1 |
| container_start_page | 210 |
| container_title | BMC cancer |
| container_volume | 23 |
| creator | Sandamali, Jayasinghe Arachchige Nirosha Hewawasam, Ruwani Punyakanthi Fernando, Madappuli Arachchige Chaminda Sri Sampath Jayatilaka, Kamani Ayoma Perera Wijewardana |
| description | The clinical application of anthracycline chemotherapy is hindered due to the cumulative dose-dependent cardiotoxicity followed by the oxidative stress initiated during the mechanism of action of anthracyclines. Due to a lack of prevalence data regarding anthracycline-induced cardiotoxicity in Sri Lanka, this study was conducted to determine the prevalence of cardiotoxicity among breast cancer patients in Southern Sri Lanka in terms of electrocardiographic and cardiac biomarker investigations.
A cross-sectional study with longitudinal follow-up was conducted among 196 cancer patients at the Teaching Hospital, Karapitiya, Sri Lanka to determine the incidence of acute and early-onset chronic cardiotoxicity. Data on electrocardiography and cardiac biomarkers were collected from each patient, one day before anthracycline (doxorubicin and epirubicin) chemotherapy, one day after the first dose, one day and six months after the last dose of anthracycline chemotherapy.
Prevalence of sub-clinical anthracycline-induced cardiotoxicity six months after the completion of anthracycline chemotherapy was significantly higher (p |
| doi_str_mv | 10.1186/s12885-023-10673-0 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_6cbe2ecb4af04a22ad18a19f473f726c</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A739619979</galeid><doaj_id>oai_doaj_org_article_6cbe2ecb4af04a22ad18a19f473f726c</doaj_id><sourcerecordid>A739619979</sourcerecordid><originalsourceid>FETCH-LOGICAL-c579t-16ad3fad795e9da4450c313b4caf47764379fc99ed3123171ddbce75efc2809b3</originalsourceid><addsrcrecordid>eNptkt-KEzEUxgdR3HX1BbyQAUH0YtZkkpkkNwvLsmqhIFi9Dmfyp5M6ndQkI9sn8LVN23VtRXKR5OT3fYckX1G8xOgSY96-j7jmvKlQTSqMWkYq9Kg4x5ThqqaIPT5anxXPYlwhhBlH_GlxRlrOkGjEefHrdjAqBa8gaOeXATa9UyWMuuycV71ZOwVD3sOwjS6W3uZ16gOorRrcaEo36kkZXR70yd855dI2l8suGIgpH4zKhHIDyZkxxdIGvy4Xfkq9CWO5CK6cw_gdnhdPLAzRvLifL4pvH26_3nyq5p8_zm6u55VqmEgVbkETC5qJxggNlDZIEUw6qsBSxlpKmLBKCKMJrglmWOtOGdYYq2qOREcuitnBV3tYyU1wawhb6cHJfcGHpYSQnBqMbFVnaqM6ChZRqGvQmAMWuQ-xrG5V9ro6eG2mbm20yvcLMJyYnp6MrpdL_1MKwRtO22zw9t4g-B-TiUmuXVRmGGA0foqyZpxQ0WDCMvr6H3Tlp5C_ZU9x2oia0r_UEvIF3Gh97qt2pvKaEdFiIZjI1OV_qDz07rv9aKzL9RPBuxNBZpK5S0uYYpSzxZdT9s0R2xsYUh_9MCXnx3gK1gdQBR9jMPbh4TCSu3zLQ75lzrfc51uiLHp1_OQPkj-BJr8BujX3QQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2788459244</pqid></control><display><type>article</type><title>Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Sandamali, Jayasinghe Arachchige Nirosha ; Hewawasam, Ruwani Punyakanthi ; Fernando, Madappuli Arachchige Chaminda Sri Sampath ; Jayatilaka, Kamani Ayoma Perera Wijewardana</creator><creatorcontrib>Sandamali, Jayasinghe Arachchige Nirosha ; Hewawasam, Ruwani Punyakanthi ; Fernando, Madappuli Arachchige Chaminda Sri Sampath ; Jayatilaka, Kamani Ayoma Perera Wijewardana</creatorcontrib><description>The clinical application of anthracycline chemotherapy is hindered due to the cumulative dose-dependent cardiotoxicity followed by the oxidative stress initiated during the mechanism of action of anthracyclines. Due to a lack of prevalence data regarding anthracycline-induced cardiotoxicity in Sri Lanka, this study was conducted to determine the prevalence of cardiotoxicity among breast cancer patients in Southern Sri Lanka in terms of electrocardiographic and cardiac biomarker investigations.
A cross-sectional study with longitudinal follow-up was conducted among 196 cancer patients at the Teaching Hospital, Karapitiya, Sri Lanka to determine the incidence of acute and early-onset chronic cardiotoxicity. Data on electrocardiography and cardiac biomarkers were collected from each patient, one day before anthracycline (doxorubicin and epirubicin) chemotherapy, one day after the first dose, one day and six months after the last dose of anthracycline chemotherapy.
Prevalence of sub-clinical anthracycline-induced cardiotoxicity six months after the completion of anthracycline chemotherapy was significantly higher (p < 0.05) and there were strong, significant (p < 0.05) associations among echocardiography, electrocardiography measurements and cardiac biomarkers including troponin I and N-terminal pro-brain natriuretic peptides. The cumulative anthracycline dose, > 350 mg/m
was the most significant risk factor associated with the sub-clinical cardiotoxicity in breast cancer patients under study.
Since these results confirmed the unavoidable cardiotoxic changes following anthracycline chemotherapy, it is recommended to carry out long-term follow-ups in all patients who were treated with anthracycline therapy to increase their quality of life as cancer survivors.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-023-10673-0</identifier><identifier>PMID: 36870959</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Age ; Anthracycline ; Anthracyclines ; Antibiotics, Antineoplastic ; Biochemical analysis ; Biomarkers ; Brain natriuretic peptide ; Breast cancer ; Breast cancer patients ; Breast Neoplasms ; Calcium-binding protein ; Cancer ; Cancer therapies ; Cardiotoxicity ; Care and treatment ; Chemotherapy ; Cross-Sectional Studies ; Diagnosis ; Dosage and administration ; Doxorubicin ; Drugs ; Echocardiography ; EKG ; Electrocardiogram ; Electrocardiography ; Enzymes ; Epirubicin ; Female ; Health aspects ; Heart ; Heart failure ; Hospitals, Teaching ; Humans ; Informed consent ; Methods ; NT-proBNP ; Oxidative stress ; Patient outcomes ; Patients ; Quality of Life ; Questionnaires ; Risk factors ; Sri Lanka ; Statistical analysis ; Teaching hospitals ; Troponin I ; Variance analysis</subject><ispartof>BMC cancer, 2023-03, Vol.23 (1), p.210-210, Article 210</ispartof><rights>2023. The Author(s).</rights><rights>COPYRIGHT 2023 BioMed Central Ltd.</rights><rights>2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c579t-16ad3fad795e9da4450c313b4caf47764379fc99ed3123171ddbce75efc2809b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985846/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2788459244?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36870959$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sandamali, Jayasinghe Arachchige Nirosha</creatorcontrib><creatorcontrib>Hewawasam, Ruwani Punyakanthi</creatorcontrib><creatorcontrib>Fernando, Madappuli Arachchige Chaminda Sri Sampath</creatorcontrib><creatorcontrib>Jayatilaka, Kamani Ayoma Perera Wijewardana</creatorcontrib><title>Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>The clinical application of anthracycline chemotherapy is hindered due to the cumulative dose-dependent cardiotoxicity followed by the oxidative stress initiated during the mechanism of action of anthracyclines. Due to a lack of prevalence data regarding anthracycline-induced cardiotoxicity in Sri Lanka, this study was conducted to determine the prevalence of cardiotoxicity among breast cancer patients in Southern Sri Lanka in terms of electrocardiographic and cardiac biomarker investigations.
A cross-sectional study with longitudinal follow-up was conducted among 196 cancer patients at the Teaching Hospital, Karapitiya, Sri Lanka to determine the incidence of acute and early-onset chronic cardiotoxicity. Data on electrocardiography and cardiac biomarkers were collected from each patient, one day before anthracycline (doxorubicin and epirubicin) chemotherapy, one day after the first dose, one day and six months after the last dose of anthracycline chemotherapy.
Prevalence of sub-clinical anthracycline-induced cardiotoxicity six months after the completion of anthracycline chemotherapy was significantly higher (p < 0.05) and there were strong, significant (p < 0.05) associations among echocardiography, electrocardiography measurements and cardiac biomarkers including troponin I and N-terminal pro-brain natriuretic peptides. The cumulative anthracycline dose, > 350 mg/m
was the most significant risk factor associated with the sub-clinical cardiotoxicity in breast cancer patients under study.
Since these results confirmed the unavoidable cardiotoxic changes following anthracycline chemotherapy, it is recommended to carry out long-term follow-ups in all patients who were treated with anthracycline therapy to increase their quality of life as cancer survivors.</description><subject>Age</subject><subject>Anthracycline</subject><subject>Anthracyclines</subject><subject>Antibiotics, Antineoplastic</subject><subject>Biochemical analysis</subject><subject>Biomarkers</subject><subject>Brain natriuretic peptide</subject><subject>Breast cancer</subject><subject>Breast cancer patients</subject><subject>Breast Neoplasms</subject><subject>Calcium-binding protein</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cardiotoxicity</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Cross-Sectional Studies</subject><subject>Diagnosis</subject><subject>Dosage and administration</subject><subject>Doxorubicin</subject><subject>Drugs</subject><subject>Echocardiography</subject><subject>EKG</subject><subject>Electrocardiogram</subject><subject>Electrocardiography</subject><subject>Enzymes</subject><subject>Epirubicin</subject><subject>Female</subject><subject>Health aspects</subject><subject>Heart</subject><subject>Heart failure</subject><subject>Hospitals, Teaching</subject><subject>Humans</subject><subject>Informed consent</subject><subject>Methods</subject><subject>NT-proBNP</subject><subject>Oxidative stress</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Quality of Life</subject><subject>Questionnaires</subject><subject>Risk factors</subject><subject>Sri Lanka</subject><subject>Statistical analysis</subject><subject>Teaching hospitals</subject><subject>Troponin I</subject><subject>Variance analysis</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkt-KEzEUxgdR3HX1BbyQAUH0YtZkkpkkNwvLsmqhIFi9Dmfyp5M6ndQkI9sn8LVN23VtRXKR5OT3fYckX1G8xOgSY96-j7jmvKlQTSqMWkYq9Kg4x5ThqqaIPT5anxXPYlwhhBlH_GlxRlrOkGjEefHrdjAqBa8gaOeXATa9UyWMuuycV71ZOwVD3sOwjS6W3uZ16gOorRrcaEo36kkZXR70yd855dI2l8suGIgpH4zKhHIDyZkxxdIGvy4Xfkq9CWO5CK6cw_gdnhdPLAzRvLifL4pvH26_3nyq5p8_zm6u55VqmEgVbkETC5qJxggNlDZIEUw6qsBSxlpKmLBKCKMJrglmWOtOGdYYq2qOREcuitnBV3tYyU1wawhb6cHJfcGHpYSQnBqMbFVnaqM6ChZRqGvQmAMWuQ-xrG5V9ro6eG2mbm20yvcLMJyYnp6MrpdL_1MKwRtO22zw9t4g-B-TiUmuXVRmGGA0foqyZpxQ0WDCMvr6H3Tlp5C_ZU9x2oia0r_UEvIF3Gh97qt2pvKaEdFiIZjI1OV_qDz07rv9aKzL9RPBuxNBZpK5S0uYYpSzxZdT9s0R2xsYUh_9MCXnx3gK1gdQBR9jMPbh4TCSu3zLQ75lzrfc51uiLHp1_OQPkj-BJr8BujX3QQ</recordid><startdate>20230304</startdate><enddate>20230304</enddate><creator>Sandamali, Jayasinghe Arachchige Nirosha</creator><creator>Hewawasam, Ruwani Punyakanthi</creator><creator>Fernando, Madappuli Arachchige Chaminda Sri Sampath</creator><creator>Jayatilaka, Kamani Ayoma Perera Wijewardana</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230304</creationdate><title>Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka</title><author>Sandamali, Jayasinghe Arachchige Nirosha ; Hewawasam, Ruwani Punyakanthi ; Fernando, Madappuli Arachchige Chaminda Sri Sampath ; Jayatilaka, Kamani Ayoma Perera Wijewardana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c579t-16ad3fad795e9da4450c313b4caf47764379fc99ed3123171ddbce75efc2809b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Age</topic><topic>Anthracycline</topic><topic>Anthracyclines</topic><topic>Antibiotics, Antineoplastic</topic><topic>Biochemical analysis</topic><topic>Biomarkers</topic><topic>Brain natriuretic peptide</topic><topic>Breast cancer</topic><topic>Breast cancer patients</topic><topic>Breast Neoplasms</topic><topic>Calcium-binding protein</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cardiotoxicity</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Cross-Sectional Studies</topic><topic>Diagnosis</topic><topic>Dosage and administration</topic><topic>Doxorubicin</topic><topic>Drugs</topic><topic>Echocardiography</topic><topic>EKG</topic><topic>Electrocardiogram</topic><topic>Electrocardiography</topic><topic>Enzymes</topic><topic>Epirubicin</topic><topic>Female</topic><topic>Health aspects</topic><topic>Heart</topic><topic>Heart failure</topic><topic>Hospitals, Teaching</topic><topic>Humans</topic><topic>Informed consent</topic><topic>Methods</topic><topic>NT-proBNP</topic><topic>Oxidative stress</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Quality of Life</topic><topic>Questionnaires</topic><topic>Risk factors</topic><topic>Sri Lanka</topic><topic>Statistical analysis</topic><topic>Teaching hospitals</topic><topic>Troponin I</topic><topic>Variance analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sandamali, Jayasinghe Arachchige Nirosha</creatorcontrib><creatorcontrib>Hewawasam, Ruwani Punyakanthi</creatorcontrib><creatorcontrib>Fernando, Madappuli Arachchige Chaminda Sri Sampath</creatorcontrib><creatorcontrib>Jayatilaka, Kamani Ayoma Perera Wijewardana</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sandamali, Jayasinghe Arachchige Nirosha</au><au>Hewawasam, Ruwani Punyakanthi</au><au>Fernando, Madappuli Arachchige Chaminda Sri Sampath</au><au>Jayatilaka, Kamani Ayoma Perera Wijewardana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2023-03-04</date><risdate>2023</risdate><volume>23</volume><issue>1</issue><spage>210</spage><epage>210</epage><pages>210-210</pages><artnum>210</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>The clinical application of anthracycline chemotherapy is hindered due to the cumulative dose-dependent cardiotoxicity followed by the oxidative stress initiated during the mechanism of action of anthracyclines. Due to a lack of prevalence data regarding anthracycline-induced cardiotoxicity in Sri Lanka, this study was conducted to determine the prevalence of cardiotoxicity among breast cancer patients in Southern Sri Lanka in terms of electrocardiographic and cardiac biomarker investigations.
A cross-sectional study with longitudinal follow-up was conducted among 196 cancer patients at the Teaching Hospital, Karapitiya, Sri Lanka to determine the incidence of acute and early-onset chronic cardiotoxicity. Data on electrocardiography and cardiac biomarkers were collected from each patient, one day before anthracycline (doxorubicin and epirubicin) chemotherapy, one day after the first dose, one day and six months after the last dose of anthracycline chemotherapy.
Prevalence of sub-clinical anthracycline-induced cardiotoxicity six months after the completion of anthracycline chemotherapy was significantly higher (p < 0.05) and there were strong, significant (p < 0.05) associations among echocardiography, electrocardiography measurements and cardiac biomarkers including troponin I and N-terminal pro-brain natriuretic peptides. The cumulative anthracycline dose, > 350 mg/m
was the most significant risk factor associated with the sub-clinical cardiotoxicity in breast cancer patients under study.
Since these results confirmed the unavoidable cardiotoxic changes following anthracycline chemotherapy, it is recommended to carry out long-term follow-ups in all patients who were treated with anthracycline therapy to increase their quality of life as cancer survivors.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>36870959</pmid><doi>10.1186/s12885-023-10673-0</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2407 |
| ispartof | BMC cancer, 2023-03, Vol.23 (1), p.210-210, Article 210 |
| issn | 1471-2407 1471-2407 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_6cbe2ecb4af04a22ad18a19f473f726c |
| source | Publicly Available Content Database; PubMed Central |
| subjects | Age Anthracycline Anthracyclines Antibiotics, Antineoplastic Biochemical analysis Biomarkers Brain natriuretic peptide Breast cancer Breast cancer patients Breast Neoplasms Calcium-binding protein Cancer Cancer therapies Cardiotoxicity Care and treatment Chemotherapy Cross-Sectional Studies Diagnosis Dosage and administration Doxorubicin Drugs Echocardiography EKG Electrocardiogram Electrocardiography Enzymes Epirubicin Female Health aspects Heart Heart failure Hospitals, Teaching Humans Informed consent Methods NT-proBNP Oxidative stress Patient outcomes Patients Quality of Life Questionnaires Risk factors Sri Lanka Statistical analysis Teaching hospitals Troponin I Variance analysis |
| title | Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T10%3A19%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Electrocardiographic%20and%20biochemical%20analysis%20of%20anthracycline%20induced%20cardiotoxicity%20in%20breast%20cancer%20patients%20from%20Southern%20Sri%20Lanka&rft.jtitle=BMC%20cancer&rft.au=Sandamali,%20Jayasinghe%20Arachchige%20Nirosha&rft.date=2023-03-04&rft.volume=23&rft.issue=1&rft.spage=210&rft.epage=210&rft.pages=210-210&rft.artnum=210&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-023-10673-0&rft_dat=%3Cgale_doaj_%3EA739619979%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c579t-16ad3fad795e9da4450c313b4caf47764379fc99ed3123171ddbce75efc2809b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2788459244&rft_id=info:pmid/36870959&rft_galeid=A739619979&rfr_iscdi=true |